After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.| Alzheimer's News Today
A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.| Alzheimer's News Today